Thalys(SH:603716)2025-10-29 10:20Financial Performance - The company's revenue for Q3 2025 was approximately ¥273.70 million, representing a decrease of 38.41% compared to the same period last year[4]. - The total profit for the period was a loss of ¥28.43 million, with a net profit attributable to shareholders of ¥31.12 million, indicating significant financial challenges[4]. - For the first nine months of 2025, the company reported a total revenue of ¥857.21 million, down 39.64% year-on-year, with a net loss of ¥87.24 million[6]. - Total revenue for the first three quarters of 2025 was ¥857,205,461.50, a decrease of 39.7% compared to ¥1,420,111,454.42 in the same period of 2024[23]. - Net loss for the first three quarters of 2025 was ¥79,153,203.33, compared to a net loss of ¥33,512,646.83 in 2024, representing a 135.7% increase in losses[24]. - Operating profit for the first three quarters of 2025 was -¥80,483,168.62, worsening from -¥50,183,819.91 in the same period of 2024[24]. - Basic and diluted earnings per share for the first three quarters of 2025 were both -¥0.44, compared to -¥0.28 in 2024[25]. Revenue Decline Factors - The company attributed the revenue decline to the transfer of certain subsidiaries and a strategic shift towards optimizing its business structure[6]. - The company is focusing on transforming its traditional medical supply chain services towards medical intelligence, which has impacted revenue and profit margins[6]. Cash Flow and Expenses - Cash flow from operating activities showed a net inflow of ¥54.57 million, reflecting a decrease in cash received from sales and services[5]. - The company has implemented cost control measures, resulting in a reduction of sales, management, and financial expenses by ¥50 million, or 18.54% year-on-year[7]. - In the first three quarters of 2025, the cash inflow from operating activities was CNY 998,060,771.28, a decrease of 38.0% compared to CNY 1,608,884,916.58 in the same period of 2024[27]. - The net cash flow from operating activities was negative at CNY -24,599,514.16, compared to a positive CNY 496,140.58 in the first three quarters of 2024[27]. - The company reported a total cash outflow from operating activities of CNY 1,022,660,285.44, compared to CNY 1,608,388,776.00 in the previous year[27]. Asset and Equity Changes - The total assets at the end of the reporting period were approximately ¥2.09 billion, a decrease of 26.14% from the previous year[5]. - The equity attributable to shareholders increased by 16.78% to ¥1.09 billion compared to the end of the previous year[5]. - Total assets decreased from ¥2,830,070,456.98 in the previous period to ¥2,090,356,280.83, a decline of 26.2%[21]. - The company's equity increased from ¥962,044,094.58 to ¥1,053,305,930.21, an increase of 9.5%[21]. Current Assets and Liabilities - The company reported a total current assets of RMB 1,381,721,482.71 as of September 30, 2025, a decrease of approximately 33.8% from RMB 2,087,128,419.96 on December 31, 2024[19]. - Cash and cash equivalents decreased to RMB 139,610,238.67 from RMB 209,435,589.90, representing a decline of about 33.3%[19]. - Accounts receivable fell to RMB 834,694,092.99, down 35.3% from RMB 1,288,755,013.77[19]. - Inventory decreased to RMB 217,162,250.62, a drop of approximately 33.4% from RMB 326,159,533.80[19]. - Total liabilities decreased from ¥1,868,026,362.40 to ¥1,037,050,350.62, a reduction of 44.4%[21]. Shareholder Information - The company has a major shareholder, Saihai (Shanghai) Health Technology Co., Ltd., holding 10.30% of shares, with 21,642,540 shares[15]. - Shanghai Anze Private Fund Management Co., Ltd. holds 5.76% of shares, totaling 12,100,399 shares[15]. - The company repurchased 3,977,700 shares, accounting for 1.89% of the total share capital as of September 30, 2025[16]. - The company has not reported any significant changes in the participation of major shareholders in margin trading or securities lending[16]. Investment Activities - The company reported an investment income of ¥7,343,276.69 in the first three quarters of 2025, compared to a loss of -¥47,577,734.26 in the same period of 2024[24]. - The cash inflow from investment activities totaled CNY 61,047,772.08, an increase of 87.0% from CNY 32,619,956.30 in the previous year[28]. - The net cash flow from investment activities was CNY 36,083,836.68, significantly up from CNY 7,540,032.26 in the same period last year[28]. - The company received CNY 19,285,848.50 from other investment-related cash activities, slightly up from CNY 18,239,609.15 in 2024[28].